Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer

Nearly one third of men will incur biochemical recurrence after treatment for localized prostate cancer. Androgen deprivation therapy (ADT) is the therapeutic mainstay; however, some patients will transition to a castrate resistant state (castrate resistant prostate cancer, CRPC). Subjects with CRPC...

Full description

Bibliographic Details
Main Authors: Stephanie Gleicher, Baylee A. Porter, Disharee Nath, Guanqun Li, Rakesh Khanna, Hanan Goldberg, Marcin Kortylewski, Gennady Bratslavsky, Leszek Kotula
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
prostate cancer
castrate resistance
non-metastatic CRPC
clinical trial
epithelial mesenchymal transition
STAT3
Online Access:https://www.mdpi.com/2072-6694/13/10/2426

Internet

https://www.mdpi.com/2072-6694/13/10/2426

Similar Items